Warfarin vs aspirin for symptomatic intracranial stenosis: Subgroup analyses from WASID

S. E. Kasner, M. J. Lynn, M. I. Chimowitz, M. R. Frankel, H. Howlett-Smith, V. S. Hertzberg, Seemant Chaturvedi, S. R. Levine, B. J. Stern, C. G. Benesch, T. G. Jovin, C. A. Sila, Jose G Romano

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

The WASID trial showed no advantage of warfarin over aspirin for preventing the primary endpoint of ischemic stroke, brain hemorrhage, or vascular death. In analyses of selected subgroups, there was no definite benefit from warfarin. Warfarin reduced the risk of the primary endpoint among patients with basilar artery stenosis, but there was no reduction in stroke in the basilar artery territory or benefit for vertebral artery stenosis or posterior circulation disease in general.

Original languageEnglish
Pages (from-to)1275-1278
Number of pages4
JournalNeurology
Volume67
Issue number7
DOIs
StatePublished - Oct 1 2006

Fingerprint

Warfarin
Vertebrobasilar Insufficiency
Aspirin
Pathologic Constriction
Stroke
Basilar Artery
Intracranial Hemorrhages
Blood Vessels

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Kasner, S. E., Lynn, M. J., Chimowitz, M. I., Frankel, M. R., Howlett-Smith, H., Hertzberg, V. S., ... Romano, J. G. (2006). Warfarin vs aspirin for symptomatic intracranial stenosis: Subgroup analyses from WASID. Neurology, 67(7), 1275-1278. https://doi.org/10.1212/01.wnl.0000238506.76873.2f

Warfarin vs aspirin for symptomatic intracranial stenosis : Subgroup analyses from WASID. / Kasner, S. E.; Lynn, M. J.; Chimowitz, M. I.; Frankel, M. R.; Howlett-Smith, H.; Hertzberg, V. S.; Chaturvedi, Seemant; Levine, S. R.; Stern, B. J.; Benesch, C. G.; Jovin, T. G.; Sila, C. A.; Romano, Jose G.

In: Neurology, Vol. 67, No. 7, 01.10.2006, p. 1275-1278.

Research output: Contribution to journalArticle

Kasner, SE, Lynn, MJ, Chimowitz, MI, Frankel, MR, Howlett-Smith, H, Hertzberg, VS, Chaturvedi, S, Levine, SR, Stern, BJ, Benesch, CG, Jovin, TG, Sila, CA & Romano, JG 2006, 'Warfarin vs aspirin for symptomatic intracranial stenosis: Subgroup analyses from WASID', Neurology, vol. 67, no. 7, pp. 1275-1278. https://doi.org/10.1212/01.wnl.0000238506.76873.2f
Kasner SE, Lynn MJ, Chimowitz MI, Frankel MR, Howlett-Smith H, Hertzberg VS et al. Warfarin vs aspirin for symptomatic intracranial stenosis: Subgroup analyses from WASID. Neurology. 2006 Oct 1;67(7):1275-1278. https://doi.org/10.1212/01.wnl.0000238506.76873.2f
Kasner, S. E. ; Lynn, M. J. ; Chimowitz, M. I. ; Frankel, M. R. ; Howlett-Smith, H. ; Hertzberg, V. S. ; Chaturvedi, Seemant ; Levine, S. R. ; Stern, B. J. ; Benesch, C. G. ; Jovin, T. G. ; Sila, C. A. ; Romano, Jose G. / Warfarin vs aspirin for symptomatic intracranial stenosis : Subgroup analyses from WASID. In: Neurology. 2006 ; Vol. 67, No. 7. pp. 1275-1278.
@article{c1997f68dab24c3aaabf521ecc2d9e52,
title = "Warfarin vs aspirin for symptomatic intracranial stenosis: Subgroup analyses from WASID",
abstract = "The WASID trial showed no advantage of warfarin over aspirin for preventing the primary endpoint of ischemic stroke, brain hemorrhage, or vascular death. In analyses of selected subgroups, there was no definite benefit from warfarin. Warfarin reduced the risk of the primary endpoint among patients with basilar artery stenosis, but there was no reduction in stroke in the basilar artery territory or benefit for vertebral artery stenosis or posterior circulation disease in general.",
author = "Kasner, {S. E.} and Lynn, {M. J.} and Chimowitz, {M. I.} and Frankel, {M. R.} and H. Howlett-Smith and Hertzberg, {V. S.} and Seemant Chaturvedi and Levine, {S. R.} and Stern, {B. J.} and Benesch, {C. G.} and Jovin, {T. G.} and Sila, {C. A.} and Romano, {Jose G}",
year = "2006",
month = "10",
day = "1",
doi = "10.1212/01.wnl.0000238506.76873.2f",
language = "English",
volume = "67",
pages = "1275--1278",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Warfarin vs aspirin for symptomatic intracranial stenosis

T2 - Subgroup analyses from WASID

AU - Kasner, S. E.

AU - Lynn, M. J.

AU - Chimowitz, M. I.

AU - Frankel, M. R.

AU - Howlett-Smith, H.

AU - Hertzberg, V. S.

AU - Chaturvedi, Seemant

AU - Levine, S. R.

AU - Stern, B. J.

AU - Benesch, C. G.

AU - Jovin, T. G.

AU - Sila, C. A.

AU - Romano, Jose G

PY - 2006/10/1

Y1 - 2006/10/1

N2 - The WASID trial showed no advantage of warfarin over aspirin for preventing the primary endpoint of ischemic stroke, brain hemorrhage, or vascular death. In analyses of selected subgroups, there was no definite benefit from warfarin. Warfarin reduced the risk of the primary endpoint among patients with basilar artery stenosis, but there was no reduction in stroke in the basilar artery territory or benefit for vertebral artery stenosis or posterior circulation disease in general.

AB - The WASID trial showed no advantage of warfarin over aspirin for preventing the primary endpoint of ischemic stroke, brain hemorrhage, or vascular death. In analyses of selected subgroups, there was no definite benefit from warfarin. Warfarin reduced the risk of the primary endpoint among patients with basilar artery stenosis, but there was no reduction in stroke in the basilar artery territory or benefit for vertebral artery stenosis or posterior circulation disease in general.

UR - http://www.scopus.com/inward/record.url?scp=33749834711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749834711&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000238506.76873.2f

DO - 10.1212/01.wnl.0000238506.76873.2f

M3 - Article

C2 - 17030766

AN - SCOPUS:33749834711

VL - 67

SP - 1275

EP - 1278

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 7

ER -